Tetrapeptide inhibiting the entry into cycle of hemopoietic stem cells processes for its preparation, and its uses

Patent Number: 5114926

This invention covers the synthethized form of a tetrapeptide that inhibits bone marrow stem cell entery into cell cycle. The original inhibitory activity was derived from fetal calf bone marrow as a biological "soup" but in this patent synthesis and structure are revealed. The use of agents that inhibit stem cell entry into cell cycle could occur when chemotherapy or radiation is administered that kills cycling cells, but if you can give an inhibitor of cell cycle entry to hematopoietic cells, then there should be preferential protection of the hematopoietic compartment. It should be stated that one of the major dose limiting toxicities of cancer chemotherpy is bone marrow toxicity.

View this patent on the USPTO website.